Literature DB >> 27084488

Investigations into the absorption of insulin and insulin derivatives from the small intestine of the anaesthetised rat.

B J McGinn1, J D Morrison2.   

Abstract

Experiments have been undertaken to determine the extent to which cholic acid conjugates of insulin were absorbed from the small intestine of anaesthetised rats by means of the bile salt transporters of the ileum. The measure used to assess the absorption of the cholyl-insulins was the amount of hypoglycaemia following infusion into the small intestine. Control experiments involving infusion of natural insulin into the ileum showed either nil absorption or absorption of a small amount of insulin as indicated by transient dip in the blood glucose concentration. However, when insulin was co-infused with the bile salt taurocholate, this was followed by a marked hypoglycaemic response which was specific to the ileum and did not occur on infusion into the jejunum. When the two cholyl conjugates of insulin were tested viz. B(29)-Lys-cholyl-insulin and B(1)-Phe-cholyl-insulin, both were biologically active as indicated by hypoglycaemic responses on systemic injection, though their potency was about 40% of that of natural insulin. While there was no evidence for the absorption of B(29)-Lys-cholyl-insulin when infused into the ileum, B(1)-Phe-cholyl-insulin did cause a long lasting hypoglycaemic response, indicating that absorption had occurred. Since the hypoglycaemic response was blocked on co-infusion with taurocholate and was absent for infusion of the conjugate into the jejunum, these results were taken as evidence that B(1)-Phe-cholyl-insulin had been taken up by the ileal bile salt transporters. This would indicate that B(1)-Phe-cholyl-insulin is worthy of further investigation for use in an oral insulin formulation.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  A21,20-S-S-B19-26 insulin decapeptide; Absorption; B(1)-Phe-cholyl-insulin; B(19)-Cys-cholyl-insulin decapeptide; B(29)-Lys-cholyl-insulin; Bovine insulin (PubChem CID: 16131099); Cholic acid; Cholic acid (PubChem CID: 221493); Cholyl-insulin; Human recombinant insulin (PubChem CID: 90488846); Ileum; Insulin; Insulin decapeptide; Jejunum; Sodium taurocholate (PubChem CID: CID: 23666345)

Mesh:

Substances:

Year:  2016        PMID: 27084488     DOI: 10.1016/j.jconrel.2016.04.002

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  2 in total

1.  Liver-targeted delivery of insulin-loaded nanoparticles via enterohepatic circulation of bile acids.

Authors:  Zhe Zhang; Hongxiang Li; Guangrui Xu; Ping Yao
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

2.  Zein-Based Nanoparticles as Oral Carriers for Insulin Delivery.

Authors:  Cristian Reboredo; Carlos J González-Navarro; Ana Luisa Martínez-López; Cristina Martínez-Ohárriz; Bruno Sarmento; Juan M Irache
Journal:  Pharmaceutics       Date:  2021-12-24       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.